EGFR is the most common driving gene of NSCLC, and the first and second generation EGFR-TKIs have become the first-line treatment for advanced NSCLC patients with positive EGFR mutation because of their better efficacy and higher survival benefits.16,17. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.